RABISHIELD

Rabishield is a monoclonal antibody designed to provide immediate protection against rabies, a deadly viral disease transmitted through the bite or scratch of an infected animal. Rabies affects the central nervous system, leading to brain inflammation and, if untreated, is almost always fatal. Rabishield is used as part of post-exposure prophylaxis (PEP) to prevent the onset of rabies after potential exposure.

How It Works

Rabishield contains a human monoclonal antibody that specifically targets the rabies virus. When administered, it provides passive immunity by neutralizing the virus at the site of entry, thereby preventing it from reaching the central nervous system. This immediate protection is crucial in the critical window following exposure to the rabies virus.

Administration

• Dosage: Rabishield is administered as a single dose based on body weight. Dose is 3.3IU/Kg body weight, Each vial has 100 IU 
• Schedule: It is given alongside the rabies vaccine as part of the post-exposure prophylaxis regimen. The vaccine is administered according to the standard rabies vaccination schedule.
• Administration Method: Rabishield is injected directly into and around the wound site (infiltration), with any remaining dose given intramuscularly.

Side Effects

Common side effects may include:

• Pain or swelling at the injection site
• Mild fever
• Headache
• Muscle pain
• Fatigue

Severe allergic reactions are rare but can occur.

Pregnancy and Lactation

• Pregnancy: Rabishield can be administered during pregnancy if there is a significant risk of rabies exposure. Consultation with a healthcare provider is recommended.
• Lactation: Safe for breastfeeding mothers, as the benefits of preventing rabies outweigh any potential risks.

Age Group

• Minimum Age: Rabishield can be administered to individuals of all ages, including infants, as part of post-exposure prophylaxis.
• Upper Age Limit: There is no upper age limit for Rabishield.

Contraindications

• Allergic Reactions: Not recommended for individuals with a known severe allergy to any component of Rabishield.
• Pre-existing Immunity: Rabishield should not be given to individuals who have been previously vaccinated against rabies and have documented adequate antibody titers.

Nature of Antigen

• Nature of Antigen: Rabishield contains a human monoclonal antibody that specifically neutralizes the rabies virus.

Vaccine Type

• Type: Rabishield is a monoclonal antibody, not a vaccine, but it is used in combination with the rabies vaccine as part of post-exposure prophylaxis.

Origin and Manufacturer

• Origin: Rabishield is an Indian product.
• Manufacturer: The antibody is produced by Serum Institute of India, one of the world's largest vaccine manufacturers.
• Introduction Year: Rabishield was introduced in 2017.

Rabishield is an essential component of rabies post-exposure prophylaxis, offering immediate protection against the rabies virus. Developed and produced by the Serum Institute of India, Rabishield provides life-saving intervention following potential rabies exposure. Always consult healthcare providers for detailed treatment protocols and personalized advice.